Publication|Articles|September 18, 2025
Supplements and Featured Publications
- Effectiveness and Safety of Arimoclomol for the Treatment of Neurological Manifestations of Niemann-Pick Disease Type C: A Review of Clinical Trial Data
Effectiveness and Safety of Arimoclomol for the Treatment of Neurological Manifestations of Niemann-Pick Disease Type C: A Review of Clinical Trial Data
Key Takeaways
- Zevra Therapeutics emphasizes innovative treatments and emerging technologies in oncology to improve patient outcomes.
- Collaboration between pharmaceutical companies and healthcare professionals is crucial for accelerating effective cancer therapy development.
Advertisement
This clinical brief is sponsored by Zevra Therapeutics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
3
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
4
How MCOs Should Be Preparing for the OBBBA's Medicaid Cuts: David Brueggeman, MBA
5
